J&J Slammed With $417 Million Verdict in California Talc Cancer Trial
The trial lasted four weeks and deliberation took two days.

Johnson & Johnson (JNJ) got hit with a $417 million verdict Monday in the first California trial evaluating an alleged link between the company's talcum powder products and ovarian cancer, Law360 reported.

The California jury set a new standard in the string of suits alleging J&J's talc products caused a woman's terminal cancer, setting a higher verdict amount than Missouri juries did.

After a four-week trial and two days of deliberation, the Los Angeles jury found Johnson & Johnson failed to warn plaintiff Eva Echeverria of the increased risk of ovarian cancer associated with use of the company's talcum products.

J&J stock traded slightly up 0.6% to $133.40 mid-afternoon Monday.

More of What's Trending on TheStreet:

More from Stocks

Record Bull Market Poised to Run Further as Trump Frets Over Fed

Record Bull Market Poised to Run Further as Trump Frets Over Fed

Famed Chartist Marc Chaikin Gives Jim Cramer His Top Picks Wednesday Aug. 22

Famed Chartist Marc Chaikin Gives Jim Cramer His Top Picks Wednesday Aug. 22

Cohen Pleads Guilty, Manafort Found Guilty -- Any Market Impact?

Cohen Pleads Guilty, Manafort Found Guilty -- Any Market Impact?

Rewalk Robotics CEO Reveals a Path to Profitability Amid Plunging Stock Price

Rewalk Robotics CEO Reveals a Path to Profitability Amid Plunging Stock Price

Stocks Trim Gains At Close After S&P 500 Sets Intraday High

Stocks Trim Gains At Close After S&P 500 Sets Intraday High